Bio-Rad Publishes Corporate Sustainability Report for 2022
July 10 2023 - 9:00AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
in life science research and clinical diagnostic products, today
released its corporate sustainability report for fiscal year ended
December 31, 2022.
The report has been prepared with reference to the Global
Reporting Initiative (GRI) 2021 Standards and in alignment with the
Sustainability Accounting Standards Board (SASB). It provides an
update on Bio-Rad’s progress towards achieving its long-term
sustainability targets including carbon emissions, operational
energy, diversity and inclusion, sustainable packaging, and ethics
and anti-corruption measures.
“During 2022, we expanded our corporate sustainability reporting
and disclosures in alignment with SASB guidelines,” said Norman
Schwartz, Bio-Rad’s Chief Executive Officer. “While we made
meaningful progress on some of our long-term sustainability goals,
we see room for continued improvement in other areas. As a company,
we have a long history of respecting the environment and the
communities in which we operate. We remain committed to advancing
our sustainability goals during the remainder of 2023 and
beyond.”
Bio-Rad’s 2022 Sustainability highlights:
- Sourced over 10% of all electricity consumed by U.S. operations
from on-site renewables, an 8% increase compared to fiscal year
2021
- Increased on-site renewable energy generation in the U.S. by
approximately 3 million kWh compared to 2021 level
- Decreased total Scope 2 emissions by 3% year-over-year
- Expanded proportion of underrepresented employees by 1% to 51%
of U.S. workforce
- Launched a recruiting program in the U.S. focused on
Historically Black Colleges and Universities
- Initiated a global labeling and packaging program to manage
sustainable packaging projects
- Began tracking supplier-related spend with small businesses,
which accounted for 23% of total supplier spend in 2022
The complete 2022 Corporate Sustainability Report is available
on the company’s website at Bio-Rad.com/sustainability.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in
developing, manufacturing, and marketing a broad range of products
for the life science research and clinical diagnostics markets.
Based in Hercules, California, Bio-Rad operates a global network of
research, development, manufacturing, and sales operations with
over 8,300 employees and $2.8 billion in revenues in 2022. Our
customers include universities, research institutions, hospitals,
food safety and environmental quality laboratories, and
biopharmaceutical companies. Together, we develop innovative,
high-quality products that advance science and save lives. To learn
more, visit bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our corporate
sustainability report, our long-term sustainability targets,
remaining committed to advancing our sustainability goals during
the remainder of 2023 and beyond, and management’s goals, plans,
expectations, future performance and other matters. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as "plan", "believe," "expect,"
"anticipate," "may," "will," "intend," "estimate," "continue," or
similar expressions or the negative of those terms or expressions,
although not all forward-looking statements contain these words.
Such statements are based on assumptions and expectations of future
events that are subject to risks and uncertainties, which could
cause actual results to vary materially from the plans, goals, and
expectations expressed in or indicated by the forward-looking
statements. These risks and uncertainties include the impact of the
COVID-19 pandemic, supply chain risks, our ability to develop and
market new or improved products, our ability to compete
effectively, international legal and regulatory risks, and product
quality and liability issues. For further information regarding our
risks and uncertainties, please refer to the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operation" in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
Bio-Rad cautions you not to place undue reliance on forward-looking
statements, which reflect an analysis only and speak only as of the
date hereof. We disclaim any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230710228837/en/
Investor Contact: Edward Chung, Investor Relations
510-741-6104 ir@bio-rad.com
Media Contact: Anna Gralinska, Corporate Communications
510-741-6643 pr@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Aug 2023 to Aug 2024